HOME >> MEDICINE >> NEWS
Free antiretroviral therapy key to success of AIDS treatment in developing countries

HIV-infected patients starting highly active antiretroviral therapy (HAART) in developing countries have increased mortality rates in the first months on therapy compared with those in developed countries, according to a paper in this week's issue of The Lancet. The authors state that early diagnosis and assessment of treatment eligibility, coupled with free provision of HAART, might reduce this excess mortality.

HAART has substantially improved the prognosis of HIV-infected patients who have access to these drugs. HAART is being scaled up in developing countries but several factors could limit the effectiveness of the therapy in resource-poor settings.

In this study the researchers compared the ART-LINC Collaboration--a network of 18 HAART programmes in Africa, Asia, and South America--with a similar network of 12 HAART programmes in Europe and North America. They found that mortality was higher in low-income settings than in high-income settings. Patients in low-income countries had lower CD4 cell counts (indicating an increased risk of infection) and more advanced clinical disease when they started treatment. However, the authors state that this only partly explains the higher mortality. They believe accompanying illnesses (comorbidities) such as tuberculosis that are present in many low-income settings may have increased mortality. They also found that the provision of treatment free of charge in low-income settings was strongly associated with lower mortality.

Author Dr Matthias Egger (University of Berne, Switzerland) concludes: "Antiretroviral therapy is feasible and effective in low income settings, but, compared with industrialized countries, mortality is high in the first months. Eligibility for antiretroviral treatment and the need for treatment of tuberculosis should be determined earlier, and HAART should be started before serious comorbidities develop."

In an accompanying Editorial, The Lancet comments: "The start of th
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
9-Mar-2006


Page: 1 2

Related medicine news :

1. Study shows interruption of antiretroviral therapy increases risk of disease and death
2. No advantage for four-drug antiretroviral regimen vs. three-drug for initial treatment of HIV-1
3. Sub-Saharan Africans with HIV may achieve favorable levels of antiretroviral therapy adherence
4. Saving antiretroviral treatment in long-term HIV-positive patients
5. Access to antiretrovirals unlikely to reduce HIV infection rates
6. Study sets new gold standard for initial antiretroviral treatment of HIV infection
7. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
8. HIV mortality in India drops with introduction of generic antiretroviral therapy
9. Highly active antiretrovirals for HIV can substantially reduce rates of AIDS
10. Chemotherapy with bevacizumab increases risk of blood clots in arteries
11. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone

Post Your Comments:
(Date:3/3/2015)... NC (PRWEB) March 03, 2015 ... Dentist in Wilmington, NC has achieved Accredited ... Dentistry. , He achieved this accomplishment after ... oral examinations, as well as the submission of ... Edgerton of Wilmington, NC grew up in Connecticut, ...
(Date:3/3/2015)... Viejo, California (PRWEB) March 03, 2015 ... animated effect entitled inMotion3D Environment from Pixel Film Studios. ... a 2D HDRI image into 360° viewing area inside ... Studios. “inMotion3D Environment blurs the line between professional and ... Motion 5 users can turn their 2D HDRI images ...
(Date:3/3/2015)... March 03, 2015 Aureus Medical Group ... Physician jobs, has announced that it will participate as ... held Tuesday, March 17, 2015 in St. Louis, MO. ... to meet job-seeking residents and fellows in a comfortable, ... division will be available to speak with attendees ...
(Date:3/3/2015)... California (PRWEB) March 03, 2015 ... announced the release of a new plugin FCPX3D Confetti ... Confetti animates an exploding transition using confetti particles inside ... “When adding an FCPX3D Confetti transition, users will have ... Plugin.” , Transition from one clip to the next ...
(Date:3/2/2015)... Atlanta, GA (PRWEB) March 02, 2015 ... FTX digital billboard design. The FTX uses state-of-the-art ... image quality, performance reliability, and owner satisfaction. An ... industry, is the exclusive Formetco 10 year LED Brightness ... was designed to be a superior billboard among any ...
Breaking Medicine News(10 mins):Health News:Dr. Edgerton, a Dentist in Wilmington, NC, Achieves Accredited Status in AACD 2Health News:A New Plugin Entitled inMotion3D Environment Was Released Today from Pixel Film Studios Exclusively for Motion 5 2Health News:A new Confetti Generator entitled FCPX3D Confetti was released today from Pixel Film Studios for Final Cut Pro X 2Health News:Formetco Launches Innovative LED Billboard System 2
(Date:3/2/2015)... March 2, 2015 Cure SMA recently announced a ... Biomedical Research (CALIBR). This funding is an extension of a ... a $700,000 Cure SMA grant to Dr. Peter G. ... "Optimization of Small Molecules that Increase SMN2 Levels ... motor neuron (SMN) protein is critical to the function of ...
(Date:3/2/2015)... GLENWOOD, Ill. , March 2, 2015  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... today announced it will release financial results for the ... Monday, March 9, 2015. The Company ... Tuesday, March 10, 2015 at 9:00 a.m. Central Time ...
(Date:3/2/2015)... Amgen (NASDAQ: AMGN ) today ... evaluating Repatha TM (evolocumab), an investigational cholesterol-lowering medication, ... chronic heart failure, at the upcoming American College of ... held March 14-16 in San Diego ... antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), ...
Breaking Medicine Technology:Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 4Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 5Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 6Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 7Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 8Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 9Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 10Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 11
Cached News: